Core Viewpoint - Outlook Therapeutics, Inc. has announced a public offering of 20,000,000 shares of common stock at a price of $0.25 per share, aiming to raise approximately $5.0 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The public offering includes 20,000,000 shares of common stock and warrants to purchase an additional 20,000,000 shares, with each warrant having an exercise price of $0.25 and expiring five years from issuance [1]. - The offering is expected to close on or about March 25, 2026, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will primarily be used for working capital and general corporate purposes [2]. Group 3: Company Overview - Outlook Therapeutics focuses on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg) to improve the standard of care for retinal diseases [5]. - LYTENAVA™ is the first ophthalmic formulation of bevacizumab to receive marketing authorization in Europe for the treatment of wet AMD, with commercial launch initiated in Germany, Austria, and the UK [5]. - In the U.S., ONS-5010/LYTENAVA™ is currently investigational and, if approved, would be the first ophthalmic formulation of bevacizumab for retinal indications [6].

Core Viewpoint - Outlook Therapeutics, Inc. has initiated a best-efforts public offering of its common stock and accompanying warrants, aimed at enhancing the standard of care for bevacizumab in treating retina diseases [1][2]. Group 1: Offering Details - The public offering is subject to market conditions, and there is no assurance regarding its completion or the actual size and terms of the offering [1]. - H.C. Wainwright & Co. is acting as the exclusive placement agent for this offering [2]. - The net proceeds from the offering will primarily be used for working capital and general corporate purposes [2]. Group 2: Regulatory and Product Information - The securities are being offered under a "shelf" registration statement filed with the SEC, which became effective on April 5, 2024 [3]. - Outlook Therapeutics is focused on the development of ONS-5010/LYTENAVA™ (bevacizumab-vikg), which is the first ophthalmic formulation of bevacizumab to receive marketing authorization in Europe for treating wet AMD [5]. - In the U.S., ONS-5010/LYTENAVA™ is still investigational, and if approved, it would be the first approved ophthalmic formulation of bevacizumab for retinal indications [6].

Core Insights - Outlook Therapeutics, Inc. announced an amendment to its existing convertible note with Avondale Capital, LLC, extending the maturity date to December 31, 2026, with no other changes to the terms [2] - The company issued a new non-convertible, unsecured note with Atlas Sciences, LLC, amounting to $18.4 million, expecting to receive $17 million in net proceeds after original issue discount [3] - Proceeds from the new note will be utilized to pay down a portion of the existing note, leaving approximately $10.8 million of principal and interest remaining [3] - The new note carries an interest rate of Prime Rate plus 3%, with a minimum interest rate of 9.5% per annum, and matures on June 16, 2027 [4] Company Overview - Outlook Therapeutics is focused on developing and commercializing ONS-5010/LYTENAVA™ (bevacizumab-vikg) to enhance the standard of care for retinal diseases [5] - LYTENAVA™ is the first ophthalmic formulation of bevacizumab to receive marketing authorization in Europe for the treatment of wet AMD, with commercial launch initiated in Germany, Austria, and the UK [5] - In the U.S., ONS-5010/LYTENAVA™ is currently investigational and, if approved, would be the first approved ophthalmic formulation of bevacizumab for retinal indications, including wet AMD [6]

Core Viewpoint - Outlook Therapeutics, Inc. is focused on enhancing the standard of care for bevacizumab in treating retina diseases and is actively engaging with the FDA to address issues raised in the Complete Response Letter for its Biologics License Application for ONS-5010/LYTENAVA™ [1][3] Regulatory Update - A Type A meeting with the FDA was held to clarify the outstanding issues regarding the evidence of effectiveness and to discuss potential regulatory pathways for approval [2] - The company aims to align with the FDA on confirmatory evidence supporting its application and to identify the most efficient pathway toward potential approval [3] Clinical Trial Results - ONS-5010/LYTENAVA™ showed clinically meaningful and statistically significant improvements in visual acuity in the NORSE TWO Phase 3 trial, meeting its primary and key secondary endpoints [4] - The NORSE EIGHT trial and other submitted information provided confirmatory evidence of efficacy and safety, supporting the successful NORSE TWO trial [4] Product Potential - If approved, ONS-5010/LYTENAVA™ would be the first FDA-approved ophthalmic formulation of bevacizumab, backed by standardized manufacturing and robust pharmacovigilance [5] - The product candidate is supported by a fully domestic, end-to-end U.S. manufacturing supply chain [5] Product Description - ONS-5010/LYTENAVA™ is an ophthalmic formulation of bevacizumab produced in the U.S. for treating wet AMD and has received Marketing Authorization in the EU and UK [6] - In the U.S., ONS-5010/LYTENAVA™ is currently investigational and, if approved, would be the first ophthalmic formulation of bevacizumab for retinal indications [10] Mechanism of Action - Bevacizumab-vikg is a recombinant humanized monoclonal antibody that binds to all isoforms of human VEGF, neutralizing its biological activity and reducing endothelial cell proliferation and vascular leakage in the retina [8]

Core Viewpoint - Outlook Therapeutics has submitted a Type A meeting request to the FDA following a Complete Response Letter regarding its Biologics License Application for ONS-5010/LYTENAVA™ for wet AMD treatment, citing a deficiency in evidence of effectiveness [1][2] Group 1: Regulatory Developments - The Complete Response Letter identified a single deficiency related to the lack of substantial evidence of effectiveness and recommended additional confirmatory evidence [2] - Outlook Therapeutics believes the FDA's determination is inconsistent with the totality of evidence submitted, including data from a well-controlled study [2] - The company conducted informal meetings with the FDA prior to submitting the Type A meeting request to discuss the CRL [2] Group 2: Clinical Evidence - ONS-5010 is supported by data from the NORSE TWO Phase 3 trial, which showed statistically significant improvements in visual acuity at 12 months, meeting its primary endpoint [3] - NORSE EIGHT, another Phase 3 study, provided additional evidence of efficacy despite not meeting its primary endpoint at 8 weeks, showing consistent gains in visual acuity [4] - A comprehensive package of confirmatory evidence was submitted, including mechanistic and pharmacodynamic data demonstrating VEGF inhibition [5] Group 3: Safety and Manufacturing - ONS-5010 demonstrated a favorable safety profile, with ocular adverse reactions consistent with the control arm and no safety concerns raised by the FDA [6] - The product is supported by a fully domestic U.S. manufacturing supply chain, enhancing reliability and aligning with public health objectives [7] Group 4: Market Authorization - LYTENAVA™ has received Marketing Authorization in the EU and UK for wet AMD treatment and became commercially available in Germany and the UK in June 2025 [8] - It is the first authorized ophthalmic formulation of bevacizumab for treating wet AMD in the EU and UK [9] - Outlook Therapeutics is exploring collaborations for commercial and distribution partnerships in additional European countries and beyond [8]

Core Viewpoint - Outlook Therapeutics, Inc. has appointed Laura Cantrell as Vice President of Corporate Strategy and Business Development to enhance its strategic initiatives and shareholder value during a critical phase of the company's evolution [3][4]. Company Overview - Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing ONS-5010/LYTENAVA™ (bevacizumab-vikg) to improve the standard of care for retinal diseases [6]. - LYTENAVA™ is the first ophthalmic formulation of bevacizumab to receive marketing authorization from the European Commission and MHRA for treating wet AMD, with a commercial launch already commenced in Germany and the UK [6]. Leadership Appointment - Laura Cantrell brings over 20 years of experience in global corporate strategy, business development, and portfolio leadership within the biotechnology and pharmaceutical sectors [4][5]. - Cantrell has held senior roles at notable companies such as Medivation, BeiGene, Sobi, Axovant Sciences, and Genentech/Roche, and has been involved in significant licensing and acquisition initiatives, including Medivation's $14 billion acquisition by Pfizer [4][5]. Strategic Focus - In her new role, Cantrell will lead the business development strategy, focusing on strategic partnerships, licensing opportunities, and corporate development initiatives to support the company's growth [3][4]. - The company aims to advance its mission of delivering a differentiated ophthalmic formulation of bevacizumab while maximizing long-term shareholder value [3].

Core Viewpoint - Outlook Therapeutics, Inc. has granted stock options to new employees as part of their compensation package, indicating a strategic move to attract talent in the biopharmaceutical sector focused on retinal diseases [1][2]. Company Overview - Outlook Therapeutics is a biopharmaceutical company dedicated to the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg), aimed at enhancing the standard of care for retinal diseases [3]. - LYTENAVA™ is the first ophthalmic formulation of bevacizumab to receive marketing authorization from the European Commission and MHRA for treating wet age-related macular degeneration (wet AMD) [3]. - The company has commenced the commercial launch of LYTENAVA™ in Germany and the UK for the treatment of wet AMD [3]. Product Development - In the United States, ONS-5010/LYTENAVA™ is currently investigational, and if approved, it would be the first ophthalmic formulation of bevacizumab for retinal indications, including wet AMD [4].

Core Insights - Outlook Therapeutics, Inc. is participating in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025 [1] - The company focuses on enhancing the standard of care for bevacizumab in treating retina diseases [3] Company Overview - Outlook Therapeutics is a biopharmaceutical company developing ONS-5010/LYTENAVA™ (bevacizumab-vikg) to improve the treatment of retina diseases [3] - LYTENAVA™ is the first ophthalmic formulation of bevacizumab to receive marketing authorization from the European Commission and MHRA for wet AMD [3] - The commercial launch of LYTENAVA™ has commenced in Germany and the UK for wet AMD treatment [3] Investigational Status - In the United States, ONS-5010/LYTENAVA™ is currently investigational [4] - If approved, it would be the first ophthalmic formulation of bevacizumab for retinal indications, including wet AMD [4]

Core Insights - The FDA has accepted the resubmission of the Biologics License Application (BLA) for ONS-5010 (bevacizumab-vikg), with a Prescription Drug User Fee Act (PDUFA) goal date set for December 31, 2025, marking a significant milestone for Outlook Therapeutics in bringing the first FDA-approved ophthalmic formulation of bevacizumab for wet age-related macular degeneration (wet AMD) to the U.S. market [1][2][7] Company Overview - Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing ONS-5010/LYTENAVA™ (bevacizumab-vikg) to enhance the standard of care for retinal diseases, particularly wet AMD [6] - The company has commenced the commercial launch of LYTENAVA™ in Germany and the UK, where it has received Marketing Authorization from the European Commission and the Medicines and Healthcare products Regulatory Agency (MHRA) [6] Product Details - ONS-5010/LYTENAVA™ is an investigational ophthalmic formulation of bevacizumab produced in the U.S. for treating wet AMD, which is currently under review in the U.S. [3][4][7] - Bevacizumab-vikg is a recombinant humanized monoclonal antibody that binds to all isoforms of human vascular endothelial growth factor (VEGF), neutralizing its activity and reducing endothelial cell proliferation and vascular leakage in the retina [5]

Core Viewpoint - Outlook Therapeutics has re-submitted its Biologics License Application (BLA) for ONS-5010 to the FDA, aiming for approval of its ophthalmic formulation of bevacizumab for treating wet age-related macular degeneration (wet AMD) [1][2] Company Overview - Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing ONS-5010/LYTENAVA™ (bevacizumab-vikg) to optimize the standard of care for retinal diseases [6] - The company has commenced the commercial launch of LYTENAVA™ in Germany and the UK for wet AMD treatment [6] Product Details - ONS-5010/LYTENAVA™ is an investigational ophthalmic formulation of bevacizumab produced in the U.S. for wet AMD [3][7] - If approved in the U.S., it would be the first approved ophthalmic formulation of bevacizumab for retinal indications, including wet AMD [7] - LYTENAVA™ has received centralized Marketing Authorization from the European Commission and the MHRA in the UK for wet AMD treatment [3][4] Regulatory Progress - The resubmission of the BLA is seen as a significant step in addressing issues raised in the Complete Response Letter (CRL) received in August 2025 [2] - The company is accelerating its commercial efforts in Europe while preparing for potential near-term U.S. approval [2]